Mitral Regurgitation

NEW ORLEANS — Transcatheter mitral valve repair for patients with HF and severe secondary mitral regurgitation reduced HF hospitalization and improved survival and functional status at 5 years vs. medical therapy alone, a speaker reported.

Access to transcatheter edge-to-edge repair for degenerative mitral regurgitation did not impact annualized surgical mitral valve repair volume, though data suggest access led to improvements in surgery outcomes and 5-year mortality rates.

In patients with HF undergoing mitral valve transcatheter edge-to-edge repair, a novel staging classification of valve disease based on extravalvular cardiac damage may improve symptomatic outcomes and survival, researchers reported.

A novel risk score comprising clinical, echocardiographic and treatment variables accurately predicted prognosis for adults with HF and severe secondary mitral regurgitation after transcatheter mitral valve repair, researchers reported.

NATIONAL HARBOR, Md. — Among PROVE-HF trial participants with HF with reduced ejection fraction and moderate to severe mitral regurgitation at baseline, sacubitril/valsartan improved mitral regurgitation severity in about half, a speaker reported.

Healio and Cardiology Today have compiled a list of the most-read news in CV intervention from TCT 2022.

BOSTON — In this Healio video exclusive, Dipti Itchhaporia, MD, FACC, FESC, discusses some of the highlights in late breaking science presented at TCT 2022.

BOSTON — A novel mitral valve transcatheter edge-to-edge repair system was noninferior to an existing system in a head-to-head trial in patients with severe symptomatic degenerative mitral regurgitation, researchers reported at TCT 2022.

Edwards Lifesciences announced its precision transcatheter mitral valve repair system for edge-to-edge repair received FDA approval for the treatment of degenerative mitral regurgitation.

Real-world safety and performance of the MitraClip NTR System and MitraClip XTR System (Abbott).